MedTrace Logo

Study of Bafetinib (INNO-406) as Treatment for Patients With Hormone-Refractory Prostate Cancer

NCT01215799 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2011-12-15

No results posted yet for this study

Summary

This is a Phase II open-label study evaluating the preliminary efficacy and safety of bafetinib administered as 240 mg orally twice daily in subjects with Hormone Refractory Prostate Cancer.

Conditions

  • Hormone Refractory Prostate Cancer

Interventions

DRUG

Bafetinib

Bafetinib 240 mg bid

Sponsors & Collaborators

  • CytRx

    lead INDUSTRY

Principal Investigators

  • Daniel Levitt, M.D., Ph.D. · Chief Medical Officer, CytRx Corporation

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2011-09-30
Completion
2011-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01215799 on ClinicalTrials.gov